Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Japanese patients with SJIA
NCT02396212Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2015
- Primary completion
- Mar 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Novartis. Primary endpoints: Percentage of Participants Who Achieved a Minimum Adapted American College of Rheumatology Pediatric 30 Criteria at 8 weeks and Percentage of Participants With Canakinumab Treatment Who Were Able to Taper Corticosteroids Successfully at 28 weeks. Started May 2015; status: completed.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT02396212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02396212.